Radiopharm Theranostics Ltd (RADX) Retained Earnings (2023 - 2025)
Radiopharm Theranostics (RADX) posted quarterly Retained Earnings of -$933322.2 for Q2 2025, down 27.2% year-over-year from -$1.3 million in Q2 2024, and down 27.2% quarter-over-quarter from -$733749.8 in Q2 2024.
Radiopharm Theranostics Ltd (RADX) Retained Earnings (2023 - 2025) Analysis & Trends
Radiopharm Theranostics (RADX) has reported Retained Earnings for 3 consecutive years, with -$933322.2 the latest figure, recorded in Q2 2025.
- In Q2 2025, Retained Earnings fell 27.2% year-over-year to -$933322.2; the TTM figure through Jun 2025 stood at -$933322.2 (down 27.2% YoY), while the FY2025 annual figure was -$145.7 million, down 30.89% from the prior year.
- Retained Earnings fell to -$933322.2 in Q2 2025 per RADX's latest filing, from -$733749.8 in the prior quarter.
- Across five years, Retained Earnings topped out at $330001.0 in Q2 2023 and bottomed at -$933322.2 in Q2 2025.
- Historically, Retained Earnings has averaged -$445690.3 across 3 years, with a median of -$733749.8 in 2024.
- Annual changes were most pronounced in 2024 — Retained Earnings sank 322.35% — and 2025, when it fell 27.2%.
- Radiopharm Theranostics' Retained Earnings stood at $330001.0 in 2023, then slumped by 322.35% to -$733749.8 in 2024, then dropped by 27.2% to -$933322.2 in 2025.
- Business Quant data shows RADX's Retained Earnings at -$933322.2 in Q2 2025, -$733749.8 in Q2 2024, and $330001.0 in Q2 2023.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -933,322.21 |
| Jun 30, 2024 | -733,749.76 |
| Jun 30, 2023 | 330,001.00 |